Computational Toxicology Communities of Practice: Celebrating Children’s Health Month - Researching Developmental Toxicity Models
Date and Time
Thursday 10/22/2020 11:00AM to 12:00PM EDTDetails
Adobe connect link and call in number will be sent after registration, check the confirmation email section at the bottom titled "Additional Information" for instructions to join.
Please feel free to forward to others who may be interested in joining!
You are invited to the EPA CompTox Communities of Practice.
Topic: Celebrating Children’s Health Month - Researching Developmental Toxicity Models
Who: Dr. Thomas Knudsen, Developmental Systems Biologist , Center for Computational Toxicology and Exposure
When: October 22, 2020 from 11:00 AM- 12:00 PM EST
Where: Register for webinar using EventbriteExit and check the confirmation email for webinar information.
Topic overview:
High-throughput in vitro assays offer a promising alternative to pregnant animal studies for assessing developmental toxicity of chemicals. Varying cells used in high-throughput screening assays have unique properties of self-renewal, pluripotency, and self-organization which help them to be excellent models of the developing embryo. Many studies have shown positive predictive value (PPV) of these cell lines for detecting developmental toxicity potential; however, translatability to pregnancy and development will require integrative computational models that recapitulate the full complementation of developmental pathways, maternal-placental toxicokinetics, and toxicodynamics of an exposed embryo.
Research under EPA’s Virtual Tissues Models is investigating the translatability of diverse cell-based platforms and computer models to evaluate effects of thousands of chemicals. A commercial platform was used to evaluate 1065 chemicals on a metabolic biomarker a cell line [Zurlinden et al. 2020]. A second platform evaluated 1047 chemicals using another cell line for a biomarker of gastrulation [Hunter et al., manuscript under review]. A challenge for science and technology is to gain a holistic understanding of the applicability domain and blind spots of cell platforms, as well as outcomes against which a PPV may be qualified. Advanced computer models and micropatterned in vitro platforms will enable recoding of cell-based data into the genomic blueprint of early development.
This abstract does not necessarily reflect U.S. EPA policy.
For more information visit the EPA's Computational Toxicology Communities of Practice webpage